Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

Abstract Background Infection with HPV 16 and 18, the major causative agents of cervical cancer, can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines provide cross-protection against HPV-types not included in the vaccines. In particular, the bivalent vaccine provides additional protection against HPV 31, 33, and 45 and the quadrivalent vaccine against HPV31. The quadrivalent vaccine additionally protects against low-risk HPV type 6 and 11, responsible for most cases of genital warts. In this study, we made an analytical comparison of the two vaccines in t... Mehr ...

Verfasser: Westra Tjalke A
Stirbu-Wagner Irina
Dorsman Sara
Tutuhatunewa Eric D
de Vrij Edwin L
Nijman Hans W
Daemen Toos
Wilschut Jan C
Postma Maarten J
Dokumenttyp: Artikel
Erscheinungsdatum: 2013
Reihe/Periodikum: BMC Infectious Diseases, Vol 13, Iss 1, p 75 (2013)
Verlag/Hrsg.: BMC
Schlagwörter: Cervical cancer / HPV-vaccination / Cost-effectiveness / Genital warts / Cross-protection / Pricing of vaccines / Infectious and parasitic diseases / RC109-216
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29169192
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1186/1471-2334-13-75